Directorio

We are doing this study to compare 2 different options for preventing strokes for people who have atrial fibrillation. We want to find out if apixaban or aspirin is the better choice to help prevent future strokes for patients with atrial fibrillation and who had a recent brain hemorrhage.

We are doing this study to find out if an experimental drug called ASP2138 (the study drug) is a safe and effective option for people with gastroesophageal junction (GEJ) cancer or metastatic pancreatic cancer.

This study has three parts: - Screening (up to 21 days): You'll get health checks like heart tests, scans, and blood work. - Study Drug Period (28-day cycles): You'll be randomly placed in one of two groups: - One group gets AZD3632 alone. -The other gets AZD3632 with another medicine called posaconazole. You'll have regular visits for tests and questions. - After Treatment: You'll have a safety check 30 days after your last dose, then visits every 12 weeks to see how your disease is doing.

In this study, people are placed into one of two groups based on certain features found in their genes. The first group, called Cohort 1, includes people who have low‑risk genetic signs. To be in this group, a person must have a mutated IGHV gene, must not have a 17p deletion, and must not have a TP53 mutation. All three conditions must be true. People in this group will first take a medicine called acalabrutinib for two cycles. After that, they will take a combination of acalabrutinib and venetoclax, called AV, for twelve more cycles. The second group, called Cohort 2, includes people who have any high‑risk genetic signs. This may include having an unmutated IGHV gene, a 17p deletion, a TP53 mutation, or a mix of these.

We are doing this study to find out if an experimental drug called ataciguant (the study drug) is an effective option to slow the rate of calcium deposits in the aortic valve for people who have aortic stenosis.

We are doing this study to find out if an experimental drug called RGX-314 (the study drug) is a safe and effective treatment for wet macular degeneration (WMD). RGX-314 is an experimental gene therapy drug that is designed to make people's bodies produce a protein that blocks the production of a bodily substance called vascular endothelial growth factor (VEGF). We want to know if this drug can continually block the production of VEGF, which might help prevent fluid build-up in the eye.

We are doing this study to find out if an experimental drug called efzofitimod (the study drug) is a safe and effective option for people with SSc-ILD. We want to know how well the study drug works against the skin and lung effects caused by SSc-ILD.

We are doing this study to find out if a study drug called belzupacap sarotalocan (bel-sar) is a safe and effective option when it is combined with laser light therapy for people who have a type of eye cancer called an indeterminate lesion (a growth in your eye that is suspected to be melanoma) or choroidal melanoma, which is also known as eye melanoma.